Threshold Pharmaceuticals, Inc.  

(Public, NASDAQ:THLD)   Watch this stock  
Find more results for THLD
-0.07 (-1.81%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.70 - 3.94
52 week 2.86 - 5.28
Open 3.91
Vol / Avg. 992,595.00/629,984.00
Mkt cap 276.54M
P/E     -
Div/yield     -
EPS -0.47
Shares 71.46M
Beta 2.94
Inst. own 59%
Nov 2, 2015
Q3 2015 Threshold Pharmaceuticals Inc Earnings Release
Sep 10, 2015
Threshold Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -174.76% -146.61%
Operating margin -184.05% -212.27%
EBITD margin - -203.38%
Return on average assets -37.43% -25.02%
Return on average equity - -
Employees 64 -
CDP Score - -


Suite 300, 170 Harbor Way
United States - Map
+1-650-4748200 (Phone)
+1-650-4742529 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Threshold Pharmaceuticals, Inc. (Threshold) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Threshold's investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Threshold's [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Officers and directors

Harold E. Selick Ph.D. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Stewart M. Kroll Senior Vice President, Clinical Development
Age: 56
Bio & Compensation  - Reuters
Robert L. Simon Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 70
Bio & Compensation  - Reuters
Joel A. Fernandes Vice President - Finance, Controller
Age: 45
Bio & Compensation  - Reuters
Nipun Davar Ph.D. Vice President - Pharmaceutical Development and Manufacturing
Age: 47
Bio & Compensation  - Reuters
Mark Hopkins J.D., Ph.D., Vice President - Intellectual Property and Assistant General Counsel
Bio & Compensation  - Reuters
Tillman Pearce M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Jeffrey W. Bird Independent Director
Age: 54
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 51
Bio & Compensation  - Reuters
David R. Hoffmann Independent Director
Age: 70
Bio & Compensation  - Reuters